90113-41-0

Upstream product

• 917-64-6 methyl magnesium iodide 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 62596-26-3 benzyl 4-oxocyclohexane-1-carboxylate 
• 2451-01-6 cis-4-hydroxy-α,α,4-trimethyl-cyclohexanemethanol, monohydrate 
• 138-87-4 beta-terpineol 
• 85734-09-4 p-menthane-1,8,9-triol 
• 7726-95-6 bromine 

Downstream Products

• 4342-60-3 4-methylcyclohex-3-enecarboxylic acid 
• 99-94-5 p-Toluic acid 
• 5034-20-8 1-(4-hydroxy-4-methylcyclohexyl)ethan-1-one 
• 20292-15-3 4-methyl-cyclohex-3-enecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

TGF-betaR1 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.